Phillips-Medisize, a medical and pharmaceutical service provider, is expanding its global manufacturing footprint, along with extended product design, development and manufacturing capabilities with new and expanded production facilities and R&D centers in Poland, China and U.S.
 
“As the preferred partner for leading global customers, we continually invest in new talent and technologies that increase the capacity and capabilities of Phillips-Medisize across the entire value chain,” said Paul Chaffin, president, Medical and Pharmaceutical Solutions, Molex. “Our expanded global reach and resources will enable us to solve complex development and manufacturing challenges while meeting escalating customer demands for more localized production, supply chain management and accelerated go-to-market strategies.”
 
To address growing production demands from customers in Europe, Phillips-Medisize is building a state-of-the-art medical manufacturing facility in Katowice, Poland, scheduled to open in 2022. The company is also expanding production capacity in Suzhou, China to serve both global and regional pharmaceutical and MedTech customers. Additionally, the transformation of an existing Molex production facility in Little Rock, Ark., is underway, to keep pace with increasing requirements in the U.S. for high-volume, diagnostic device manufacturing. 
 
“We’re excited to leverage Phillips-Medisize’s world-class manufacturing as we scale toward high-volume automation at the new state-of-the-art facility in Poland,” said Jeff Tillack, COO at Credence MedSystems. “The opportunity to scale production in close proximity to our operations and European customers will accelerate market delivery of our innovative solutions to meet the needs of our pharma customers and their end-users.”